ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.
Hosted on MSN
AI is reshaping GPCR drug discovery
Artificial intelligence is accelerating breakthroughs in G protein-coupled receptor (GPCR) research, a key area for developing new medicines. From predicting complex receptor structures to screening ...
Abstract: Cancer therapy peptides (CTPs), as multifunctional peptides, possess the ability to target cancer cells or related proteins, exhibiting significant therapeutic potential. However, ...
Protein–protein interaction (PPI) and their interaction sites [PPI site (PPIS)] hold immense potential for elucidating cellular mechanisms and advancing targeted drug development. While deep learning ...
A detailed new map of the human kidney revealed a previously unrecognized form of diabetic kidney disease (DKD) marked by ...
The rapid advances in machine learning (ML) and artificial intelligence (AI) are transforming biology and opening new directions for scientific inquiry.
Researchers from the National Institute for Physiological Sciences, Nagoya City University, and Tokyo Metropolitan Institute ...
Summary: For over a century, potassium ions were viewed as mere passengers in the brain—particles that flow through channels ...
This manuscript has convincing data that provides a high-resolution structure of the Egl-RNA complex. The findings are important to understand the formation, stability, and interactions of this ...
Okazaki, Japan, 22 April 2026 – Potassium ions (K⁺) are essential for all cells and living organisms. Scientists have long believed that K⁺ merely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results